Price (delayed)
$9.36
Market cap
$334.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.72
Enterprise value
$136.48M
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of
There are no recent dividends present for ITOS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.